Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Occupational Exposure

The legacy domain has established a foundation in general health and science information, providing a broad audience with accessible knowledge on medical conditions and treatments. Within this context, discussions of medication safety and adverse effects have been a recurring theme, particularly regarding widely prescribed drugs. Fosamax, a bisphosphonate used for osteoporosis, has been part of this general health discourse, with attention to its potential side effects. As the focus narrows from broad health education to specific occupational exposure concerns, a pivot is warranted. In mass production environments, workers may encounter pharmaceutical compounds during manufacturing, handling, or packaging processes. This transition shifts the lens from patient-oriented information to the risks faced by personnel in industrial settings. The concern here is not about clinical prescription but about exposure during production workflows, where inhalation or dermal contact with active ingredients could occur. Osteonecrosis of the jaw, a condition previously discussed in patient contexts, now becomes relevant as a potential occupational hazard for those involved in Fosamax manufacturing. This reframing allows for an examination of workplace safety protocols, exposure limits, and monitoring practices, moving from general health literacy to targeted industrial hygiene considerations.

Understanding Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism of action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence. However, a recognized adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves areas of exposed bone that persist for more than eight weeks, often accompanied by pain, swelling, infection, or drainage. Diagnosis is primarily clinical, based on visual examination and patient history, and may be supported by imaging studies to rule out other causes. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Scientific Evidence Linking Fosamax to ONJ

The scientific evidence connecting Fosamax to ONJ is supported by multiple lines of investigation. Pharmacologically, bisphosphonates like alendronate accumulate in bone tissue, particularly at sites of high bone turnover such as the jaw. This accumulation can suppress osteoclast activity, impairing normal bone remodeling and repair. The jawbone's unique structure and high remodeling rate may make it especially susceptible to bisphosphonate-related complications. A multiscale characterization of jawbone treated with osteoporosis therapeutic agents in estrogen-deficient rats found that bisphosphonate (alendronate) treatment affected the jawbone, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Mechanistic pathways linking Fosamax to ONJ involve several processes. Bisphosphonates inhibit farnesyl pyrophosphate synthase in the mevalonate pathway, disrupting osteoclast function and survival. This leads to reduced bone resorption and turnover, which can impair the ability of the jawbone to heal after minor trauma or dental procedures. Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone and increasing the risk of necrosis. The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Causation Considerations

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw. The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It also notes that the time to onset of symptoms varied from one day to several months after starting the drug, and that most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized risk, its incidence in clinical trials was low and not statistically different from placebo, which may affect the perception of risk. Causation-related considerations for affected patients are complex. Establishing a causal link between Fosamax and ONJ requires careful evaluation of individual patient factors, including duration of bisphosphonate use, presence of other risk factors, and temporal relationship between drug exposure and onset of symptoms. The timeline between exposure and documented harm can vary widely, with onset of symptoms ranging from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A subset of patients had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), further supporting a drug-related effect. However, ONJ can also occur spontaneously in the absence of bisphosphonate use, complicating attribution. In summary, the scientific evidence demonstrates a plausible association between Fosamax and osteonecrosis of the jaw, supported by pharmacological mechanisms, preclinical studies, and clinical reports. The risk is influenced by duration of use, dental procedures, and other patient-specific factors. While warnings are included in the prescribing information, the low incidence in clinical trials and the multifactorial nature of ONJ require careful consideration in individual cases.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the scientific evidence linking Fosamax to osteonecrosis of the jaw?

The scientific evidence includes pharmacological mechanisms where bisphosphonates accumulate in bone, suppress osteoclast activity, and impair bone remodeling. Preclinical studies, such as a multiscale characterization in rats (https://pubmed.ncbi.nlm.nih.gov/40345077/), show effects on jawbone properties. Clinical reports and prescribing information also document ONJ in patients taking Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ from Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and pre-existing dental disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Duration of bisphosphonate use also increases risk.

How is ONJ diagnosed and what are its symptoms?

ONJ is diagnosed clinically by visual examination and patient history, with imaging to rule out other causes. Symptoms include exposed bone in the jaw persisting for more than eight weeks, pain, swelling, infection, or drainage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.